202 related articles for article (PubMed ID: 16409469)
21. Effect of activated recombinant human factor 7 (Niastase) on laboratory testing of inhibitors of factors VIII and IX.
Keeney M; Allan DS; Lohmann RC; Yee IH
Lab Hematol; 2005; 11(2):118-23. PubMed ID: 16024335
[TBL] [Abstract][Full Text] [Related]
22. Mechanism by which recombinant factor VIIa shortens the aPTT: activation of factor X in the absence of tissue factor.
Telgt DS; Macik BG; McCord DM; Monroe DM; Roberts HR
Thromb Res; 1989 Dec; 56(5):603-9. PubMed ID: 2626745
[TBL] [Abstract][Full Text] [Related]
23. Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses.
Kjalke M; Kjelgaard-Hansen M; Andersen S; Hilden I
J Thromb Haemost; 2021 Jul; 19(7):1687-1696. PubMed ID: 33819375
[TBL] [Abstract][Full Text] [Related]
24. The role of platelets and recombinant factor VIIa on thrombin generation, platelet activation and clot formation.
Gerotziafas GT; Chakroun T; Depasse F; Arzoglou P; Samama MM; Elalamy I
Thromb Haemost; 2004 May; 91(5):977-85. PubMed ID: 15116259
[TBL] [Abstract][Full Text] [Related]
25. Variants of recombinant factor VIIa with increased intrinsic activity.
Persson E
Semin Hematol; 2004 Jan; 41(1 Suppl 1):89-92. PubMed ID: 14872428
[TBL] [Abstract][Full Text] [Related]
26. Combined administration of FVIII and rFVIIa improves haemostasis in haemophilia A patients with high-responding inhibitors--a thrombin generation-guided pilot study.
Livnat T; Martinowitz U; Azar-Avivi S; Zivelin A; Brutman-Barazani T; Lubetsky A; Kenet G
Haemophilia; 2013 Sep; 19(5):782-9. PubMed ID: 23659442
[TBL] [Abstract][Full Text] [Related]
27. Recombinant factor VIIa analog NN1731 (V158D/E296V/M298Q-FVIIa) enhances fibrin formation, structure and stability in lipidated hemophilic plasma.
Gray LD; Hussey MA; Larson BM; Machlus KR; Campbell RA; Koch G; Ezban M; Hedner U; Wolberg AS
Thromb Res; 2011 Dec; 128(6):570-6. PubMed ID: 21561645
[TBL] [Abstract][Full Text] [Related]
28. Recombinant factor VIIa enhances platelet adhesion and activation under flow conditions at normal and reduced platelet count.
Lisman T; Adelmeijer J; Cauwenberghs S; Van Pampus EC; Heemskerk JW; De Groot PG
J Thromb Haemost; 2005 Apr; 3(4):742-51. PubMed ID: 15842358
[TBL] [Abstract][Full Text] [Related]
29. Mechanism of action of recombinant activated factor VII: an update.
Hedner U
Semin Hematol; 2006 Jan; 43(1 Suppl 1):S105-7. PubMed ID: 16427375
[TBL] [Abstract][Full Text] [Related]
30. Recombinant factor VIIa enhances platelet deposition from flowing haemophilic blood but requires the contact pathway to promote fibrin deposition.
Li R; Panckeri KA; Fogarty PF; Diamond SL
Haemophilia; 2015 Mar; 21(2):266-274. PubMed ID: 25311576
[TBL] [Abstract][Full Text] [Related]
31. Factor VIII activation by factor VIIa analog (V158D/E296V/M298Q) in tissue factor-independent mechanisms.
Ogiwara K; Nogami K; Shima M
Thromb Haemost; 2011 Oct; 106(4):665-74. PubMed ID: 21901232
[TBL] [Abstract][Full Text] [Related]
32. Effects of coagulation factor deficiency on plasma coagulation kinetics determined via thrombelastography: critical roles of fibrinogen and factors II, VII, X and XII.
Nielsen VG; Cohen BM; Cohen E
Acta Anaesthesiol Scand; 2005 Feb; 49(2):222-31. PubMed ID: 15715625
[TBL] [Abstract][Full Text] [Related]
33. Antithrombin affects hemostatic response to recombinant activated factor VII in factor VIII deficient plasma.
Szlam F; Taketomi T; Sheppard CA; Kempton CL; Levy JH; Tanaka KA
Anesth Analg; 2008 Mar; 106(3):719-24, table of contents. PubMed ID: 18292408
[TBL] [Abstract][Full Text] [Related]
34. Unifying the mechanism of recombinant FVIIa action: dose dependence is regulated differently by tissue factor and phospholipids.
Shibeko AM; Woodle SA; Lee TK; Ovanesov MV
Blood; 2012 Jul; 120(4):891-9. PubMed ID: 22563088
[TBL] [Abstract][Full Text] [Related]
35. New insights into the coagulation system and implications for new therapeutic options with recombinant factor VIIa.
Veldman A; Hoffman M; Ehrenforth S
Curr Med Chem; 2003 May; 10(10):797-811. PubMed ID: 12678684
[TBL] [Abstract][Full Text] [Related]
36. Effects of factor VIII inhibitor bypassing activity (FEIBA), recombinant factor VIIa or both on thrombin generation in normal and haemophilia A plasma.
Livnat T; Martinowitz U; Zivelin A; Seligsohn U
Haemophilia; 2008 Jul; 14(4):782-6. PubMed ID: 18371162
[TBL] [Abstract][Full Text] [Related]
37. The function of factor XI in tissue factor-initiated thrombin generation.
Butenas S; Dee JD; Mann KG
J Thromb Haemost; 2003 Oct; 1(10):2103-11. PubMed ID: 14521591
[TBL] [Abstract][Full Text] [Related]
38. Activated factor X and thrombin formation triggered by tissue factor on endothelial cell matrix in a flow model: effect of the tissue factor pathway inhibitor.
van 't Veer C; Hackeng TM; Delahaye C; Sixma JJ; Bouma BN
Blood; 1994 Aug; 84(4):1132-42. PubMed ID: 8049429
[TBL] [Abstract][Full Text] [Related]
39. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency.
Scharrer I
Haemophilia; 1999 Jul; 5(4):253-9. PubMed ID: 10469179
[TBL] [Abstract][Full Text] [Related]
40. Effect of recombinant factor VIIa (Novoseven) on thrombocytopenia-like conditions in vitro.
Kjalke M; Johannessen M; Hedner U
Semin Hematol; 2001 Oct; 38(4 Suppl 12):15-20. PubMed ID: 11735105
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
